Morvus Technology Ltd is a pharmaceutical company formed in April 2004 to exploit its founders’ proven expertise in the areas of drug and target-discovery and the commercialisation of novel technology. Its primary focus is oncology.
Morvus was established by an experienced management team who were previously the founders and senior executives of Enact Pharma Plc, which was acquired in June 2003 by Protherics Plc. In April 2004 the team negotiated a management buy-out from Protherics acquiring some niche early-stage programmes and technology and an asset-base of equipment. Since then Morvus has substantially increased the value of the business via the creation of a product-rich portfolio derived out of a suite of programmes outside the original buy-out.
In October 2007 Morvus completed the acquisition of two specia Click for details>>
United Kingdom
